- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- O6-benzylguanine, temozolomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 776
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain
- Interventions
- C134
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging
- Drug · Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Malignant Glioma
- Interventions
- Carboplatin, Cyclophosphamide, Etoposide Phosphate, Quality-of-Life Assessment, Sodium Thiosulfate
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2024
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Cleveland, Ohio • Portland, Oregon
- Conditions
- Cancer
- Interventions
- cyproheptadine hydrochloride, placebo
- Drug · Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 14
- States / cities
- Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab
- Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Buffalo, New York • Charlottesville, Virginia
- Conditions
- Glioblastoma Multiforme, High-Grade Glioma
- Interventions
- Gliadel wafer, Temozolomide, External Beam Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Methodist Healthcare - Memphis
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study, dexamethasone
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more
- Conditions
- Brain Neoplasms
- Interventions
- Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
- Drug · Radiation · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
- Conditions
- Brain Tumor, Central Nervous System Tumor
- Interventions
- carboplatin, temozolomide, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 10 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, High Grade Glioma, GBM, Brain Cancer
- Interventions
- Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
- Procedure
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma, Metastatic Cancer, Retinoblastoma, Sarcoma
- Interventions
- busulfan
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 8
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Retinoblastoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- filgrastim, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Malignant Central Nervous System Neoplasm, Malignant Skull Base Neoplasm
- Interventions
- Medical Chart Review
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Intracranial Neoplasms, Neoplasms, Brain, Neoplasms, Intracranial, Primary Brain Neoplasms, Primary Malignant Brain Neoplasms, Primary Malignant Brain Tumors, Gliomas, Glioblastoma
- Interventions
- 5-ALA (Gliolan)
- Drug
- Lead sponsor
- Constantinos Hadjipanayis
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more
- Conditions
- Brain Tumor, Medulloblastoma, Brain Metastases
- Interventions
- WP1066
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor, Kidney Tumor
- Interventions
- doxorubicin HCl liposome
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Malignant Glioma (WHO Grade III or IV)
- Interventions
- CTO and Bevacizumab, CTO alone
- Drug
- Lead sponsor
- Annick Desjardins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Interventions
- Dual-Energy Computed Tomography
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chondrosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Rhabdomyosarcoma, Adult Malignant Meningioma, Adult Brain Malignant Hemangiopericytoma
- Interventions
- ifosfamide
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 65
- States / cities
- Scottsdale, Arizona • Duarte, California • Palo Alto, California + 46 more
- Conditions
- Brain Tumors
- Interventions
- temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Lihue, Hawaii + 13 more
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer
- Interventions
- temozolomide, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study, conventional surgery, stereotactic radiosurgery
- Drug · Other · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
- Interventions
- filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Up to 10 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 17
- States / cities
- Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer
- Interventions
- sunitinib malate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York